serine has been researched along with Psychoses in 28 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Schizophrenia is associated with deficits in cortical plasticity that affect sensory brain regions and lead to impaired cognitive performance." | 6.82 | Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. ( Ahissar, M; Beggel, O; Epstein, ML; Javitt, DC; Kantrowitz, JT; Lehrfeld, JM; Lehrfeld, NP; Parker, E; Reep, J; Revheim, N; Rohrig, S; Silipo, G, 2016) |
| "Subjects had DSM-IV schizophrenia or schizoaffective disorder and were inpatients or outpatients stabilized on antipsychotics, with persistent negative symptoms." | 6.77 | A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. ( Abramovich, Y; Amital, D; Davidson, M; Doron, A; Gershon, AA; Heresco-Levy, U; Javitt, DC; Konas, S; Levkovitz, Y; Liba, D; Mashiach, M; Teitelbaum, A; Weiser, M; Werbeloff, N; Zimmerman, Y, 2012) |
| "Plasma serine levels (PSL) in a group of patients with the diagnosis of major or atypical psychoses were significantly higher than in patients with nonpsychotic diagnoses or nonpatient controls." | 3.67 | Serine metabolism and psychosis. ( Mott, J; Sherman, AD; Waziri, R; Wilcox, J, 1984) |
| "It was investigated whether an increased demand for glycine, as postulated to occur in patients who have suffered from episodic psychoses accompanied by multiple perceptual distortions, could evoke psychotic reactions." | 3.66 | Serine and glycine-induced catalepsy in porphyric rats: an animal model for psychosis? ( Bruinvels, J; Pepplinkhuizen, L; Schouten, MJ; Wilson, JH, 1983) |
| "Schizophrenia is associated with deficits in cortical plasticity that affect sensory brain regions and lead to impaired cognitive performance." | 2.82 | Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine. ( Ahissar, M; Beggel, O; Epstein, ML; Javitt, DC; Kantrowitz, JT; Lehrfeld, JM; Lehrfeld, NP; Parker, E; Reep, J; Revheim, N; Rohrig, S; Silipo, G, 2016) |
| "Subjects had DSM-IV schizophrenia or schizoaffective disorder and were inpatients or outpatients stabilized on antipsychotics, with persistent negative symptoms." | 2.77 | A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. ( Abramovich, Y; Amital, D; Davidson, M; Doron, A; Gershon, AA; Heresco-Levy, U; Javitt, DC; Konas, S; Levkovitz, Y; Liba, D; Mashiach, M; Teitelbaum, A; Weiser, M; Werbeloff, N; Zimmerman, Y, 2012) |
| "Haloperidol-treated rats were divided into groups of DSP rats and non-DSP rats based on locomotion data." | 1.46 | Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats. ( Fujita, Y; Hashimoto, K; Iyo, M; Kanahara, N; Nakata, Y; Niitsu, T; Oda, Y; Oishi, K; Shirayama, Y; Takase, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (28.57) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 7 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garip, B | 1 |
| Kayir, H | 1 |
| Oda, Y | 1 |
| Fujita, Y | 1 |
| Oishi, K | 1 |
| Nakata, Y | 1 |
| Takase, M | 1 |
| Niitsu, T | 1 |
| Kanahara, N | 1 |
| Shirayama, Y | 1 |
| Hashimoto, K | 1 |
| Iyo, M | 1 |
| Sasabe, J | 1 |
| Suzuki, M | 1 |
| Li, C | 1 |
| Wang, A | 1 |
| Wang, C | 1 |
| Ramamurthy, J | 1 |
| Zhang, E | 1 |
| Guadagno, E | 1 |
| Trakadis, Y | 1 |
| Pinacho, R | 1 |
| Saia, G | 1 |
| Fusté, M | 1 |
| Meléndez-Pérez, I | 1 |
| Villalta-Gil, V | 1 |
| Haro, JM | 1 |
| Gill, G | 1 |
| Ramos, B | 1 |
| Kantrowitz, JT | 1 |
| Epstein, ML | 1 |
| Beggel, O | 1 |
| Rohrig, S | 1 |
| Lehrfeld, JM | 1 |
| Revheim, N | 1 |
| Lehrfeld, NP | 1 |
| Reep, J | 1 |
| Parker, E | 1 |
| Silipo, G | 1 |
| Ahissar, M | 1 |
| Javitt, DC | 2 |
| Weiser, M | 1 |
| Heresco-Levy, U | 1 |
| Davidson, M | 1 |
| Werbeloff, N | 1 |
| Gershon, AA | 1 |
| Abramovich, Y | 1 |
| Amital, D | 1 |
| Doron, A | 1 |
| Konas, S | 1 |
| Levkovitz, Y | 1 |
| Liba, D | 1 |
| Teitelbaum, A | 1 |
| Mashiach, M | 1 |
| Zimmerman, Y | 1 |
| Sumiyoshi, T | 1 |
| Anil, AE | 1 |
| Jin, D | 1 |
| Jayathilake, K | 1 |
| Lee, M | 1 |
| Meltzer, HY | 2 |
| Shizuka, K | 1 |
| Yoneda, H | 1 |
| Bakker, PR | 1 |
| van Harten, PN | 1 |
| van Os, J | 1 |
| DeRosse, P | 1 |
| Hodgkinson, CA | 1 |
| Lencz, T | 1 |
| Burdick, KE | 1 |
| Kane, JM | 1 |
| Goldman, D | 2 |
| Malhotra, AK | 2 |
| Verhoeven, WM | 1 |
| Van Ravenswaaij-Arts, CM | 1 |
| De Leeuw, N | 1 |
| Fekkes, D | 4 |
| Van der Heijden, FM | 1 |
| Egger, JI | 1 |
| Tuinier, S | 1 |
| Pepplinkhuizen, L | 6 |
| Bruinvels, J | 5 |
| Blom, W | 1 |
| Moleman, P | 1 |
| Waziri, R | 6 |
| Wilcox, J | 2 |
| Sherman, AD | 2 |
| Mott, J | 3 |
| Wilson, R | 1 |
| Schouten, MJ | 1 |
| Wilson, JH | 1 |
| Verheij, R | 1 |
| Brown, FW | 1 |
| Devor, EJ | 1 |
| Bode, WT | 1 |
| Zijlstra, FJ | 1 |
| Sasaki, T | 1 |
| Macciardi, FM | 1 |
| Badri, F | 1 |
| Verga, M | 1 |
| Lieberman, J | 1 |
| Howard, A | 1 |
| Bean, G | 1 |
| Joffe, RT | 1 |
| Hudson, CJ | 1 |
| Kennedy, JL | 1 |
| Ozaki, N | 1 |
| Rooney, W | 1 |
| Clifton, A | 1 |
| Buchanan, RW | 1 |
| Breier, A | 1 |
| Pickar, D | 1 |
| Serretti, A | 1 |
| Lattuada, E | 1 |
| Lorenzi, C | 1 |
| Lilli, R | 1 |
| Smeraldi, E | 1 |
| Sherman, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot[NCT02156908] | Phase 2 | 8 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| D-Serine Adjuvant Pharmacotherapy for the Treatment of Schizophrenia[NCT00138775] | Phase 2 | 200 participants | Interventional | 2004-10-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"An MMN event is evoked by a discernible change in the pitch of a repetitive auditory stimulation. The stronger the response to a difference (i.e., the more negative the amplitude of the MMN), the better the outcome.~MMN was obtained to pitch deviant stimuli pre-post auditory plasticity training, utilizing deviants to the same base frequencies as the auditory plasticity sessions, (i.e. 500, 1000, and 2000 Hz), with ~10 minutes of each base frequency. MMN will be conducted at baseline and after the final session. Reported outcome is change in MMN between baseline and final within session." (NCT02156908)
Timeframe: 3 weeks
| Intervention | micro volts (Mean) |
|---|---|
| D-serine | .086 |
| no Intervention | 0.31 |
Change tone matching threshold (the percent difference in pitch of two consecutively played tones that can be distinguished), higher numbers represent better outcomes. D-serine outcomes are for 2 consecutive D-serine sessions (NCT02156908)
Timeframe: three weeks
| Intervention | percentage of difference in pitch (Mean) |
|---|---|
| D-serine | 11 |
| No Intervention | 2.3 |
4 reviews available for serine and Psychoses
| Article | Year |
|---|---|
Distinctive Roles of D-Amino Acids in the Homochiral World: Chirality of Amino Acids Modulates Mammalian Physiology and Pathology.
Topics: Amino Acids; Animals; Archaea; Bacteria; D-Aspartic Acid; Endocrine System; Humans; Immunity, Innate | 2019 |
Metabolomics in patients with psychosis: A systematic review.
Topics: 3-Hydroxybutyric Acid; Aspartic Acid; Biomarkers; Bipolar Disorder; Creatine; Female; Glutamic Acid; | 2018 |
[Outcome of genetic studies on atypical psychoses].
Topics: Chromosomes, Human, Pair 1; Cysteine; Genetic Predisposition to Disease; Haplotypes; Humans; Membran | 2004 |
The neurobiology of late-life psychosis.
Topics: Aged; Brain; Dopamine; Electroencephalography; Evoked Potentials; Humans; Magnetic Resonance Imaging | 1993 |
3 trials available for serine and Psychoses
| Article | Year |
|---|---|
Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Topics: Adult; Auditory Perceptual Disorders; Brain Waves; Cohort Studies; Evoked Potentials, Auditory; Exci | 2016 |
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Topics: Adult; Antipsychotic Agents; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Huma | 2012 |
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.
Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Female; Glycine; Humans; Ma | 2004 |
21 other studies available for serine and Psychoses
| Article | Year |
|---|---|
Alteration in NMDAR-related amino acids in first episode psychosis.
Topics: Asparagine; Chromatography, Liquid; Female; Glutamic Acid; Glutamine; Humans; Hydroxyproline; Male; | 2019 |
Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
Topics: Animals; Antipsychotic Agents; Brain; Dopamine; Glutamate Decarboxylase; Glutamic Acid; Glutamine; H | 2017 |
Phosphorylation of transcription factor specificity protein 4 is increased in peripheral blood mononuclear cells of first-episode psychosis.
Topics: Adolescent; Adult; Animals; Antipsychotic Agents; Benzodiazepines; Cells, Cultured; Cross-Sectional | 2015 |
Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
Topics: Alleles; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Glycine; H | 2006 |
Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.
Topics: Cysteine; Delusions; Genetic Carrier Screening; Genetic Predisposition to Disease; Genotype; Halluci | 2007 |
Disturbed serine metabolism and psychosis in a patient with a de novo translocation (2;10)(p23;q22.1).
Topics: Adult; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 2; DiGeorge Syndrome; Female; Humans; H | 2006 |
Schizophrenia-like psychosis caused by a metabolic disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Diagnosis, Differential; Female; Glycine; Humans; Porphyria | 1980 |
Serine metabolism and psychosis.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Diet; Glycine; Glycine Hydroxymethyltra | 1984 |
Plasma serine to cysteine ratio as a biological marker for psychosis.
Topics: Adolescent; Adult; Chromatography, Gas; Cysteine; Female; Humans; Male; Middle Aged; Psychotic Disor | 1983 |
Serine and glycine-induced catalepsy in porphyric rats: an animal model for psychosis?
Topics: Allylisopropylacetamide; Aminolevulinic Acid; Animals; Catalepsy; Disease Models, Animal; Glycine; H | 1983 |
Abnormal plasma levels of serine, methionine, and taurine in transient acute polymorphic psychosis.
Topics: Adult; Bipolar Disorder; Diagnosis, Differential; Female; Humans; Male; Methionine; Middle Aged; Psy | 1994 |
A familial/genetic study of plasma serine and glycine concentrations.
Topics: Dopamine; Female; gamma-Aminobutyric Acid; Glucose; Glutamates; Glycine; Humans; Internal-External C | 1993 |
Eicosanoid and amino acid metabolism in transient acute psychoses with psychedelic symptoms.
Topics: Adult; Female; Glutathione; Humans; Male; Methionine; Prostaglandins E; Psychotic Disorders; Serine; | 1996 |
No evidence for association of dopamine D2 receptor variant (Ser311/Cys311) with major psychosis.
Topics: Adult; Age of Onset; Amino Acid Sequence; Bipolar Disorder; Cysteine; Delusions; Female; Genetic Var | 1996 |
Clozapine response and the 5HT2C Cys23Ser polymorphism.
Topics: Alleles; Antipsychotic Agents; Base Sequence; Clozapine; Cysteine; DNA Primers; Female; Genetic Carr | 1996 |
Dopamine receptor D2 Ser/Cys 311 variant is associated with delusion and disorganization symptomatology in major psychoses.
Topics: Adult; Amino Acid Substitution; Bipolar Disorder; Cysteine; Depressive Disorder; Female; Genetic Var | 2000 |
Changes in serine metabolism by a serum factor present in a group of episodic psychotic patients.
Topics: Amino Acids; Cell Line; Cells, Cultured; Cystathionine beta-Synthase; Fibroblasts; Glycine Hydroxyme | 1991 |
Drug effects on serine metabolism in psychiatric patients.
Topics: Antipsychotic Agents; Glycine Hydroxymethyltransferase; Humans; Mental Disorders; Psychotic Disorder | 1986 |
Serine, glycine and carbohydrates in schizoaffective disorders.
Topics: Amino Acids; Dietary Carbohydrates; Glycine; Humans; Psychotic Disorders; Reference Values; Serine | 1986 |
Serine metabolism, psychosis, and coeliac disease.
Topics: Celiac Disease; Humans; Psychotic Disorders; Risk; Serine | 1985 |
Metabolism of an ingested serine load in psychotic and nonpsychotic subjects.
Topics: Age Factors; Glycine; Glycine Hydroxymethyltransferase; Humans; Leucine; Metabolic Clearance Rate; P | 1985 |